Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic

Thoughts from our Chairman and CEO on a year defined by loss, learning and an approaching liberation.

Annual Review Highlights a Historic Year

2020 was a year of unique challenges and record-breaking innovations.

Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2

Pfizer announced that they've started testing the safety profile of their novel oral antiviral investigational drug candidate for SARS-CoV-2 infections.

Biosimilars: Advancing Science to Help Improve Patient Access to Medicines

Biologics are among the most powerful drugs to treat cancer and autoimmune diseases today. Made from living organisms, such as bacteria or yeast, these therapies can specifically target cells or stimulate the immune system to fight tumors or inflammation.

Join the Pfizer Plus Community Corner

When you join the community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • Community